Tesamorelin + Ipamorelin Blend: Research Strength Considerations

For a wholesale buyer, "research strength" in a tesamorelin + ipamorelin blend comes down to one thing: the declared mass of each peptide in the vial, independently confirmed. A label that gives only a combined total — "20mg blend" — tells you nothing usable, because the two compounds are structurally and chemically unlike each other and cannot be assayed as a single entity. What you need before any blended vial enters your catalog is per-component mass, per-component chromatographic purity, identity confirmation for each peptide, and a batch-matched certificate of analysis you can read without asking for it. Everything else in the sourcing decision — stability, packaging, lead time, supplier credibility — follows from whether that documentation exists and whether it is published.

These are research-use-only compounds. Real Peptides does not publish dosing, preparation, or administration guidance for any item in the catalog, and nothing below should be read as such. What follows is procurement and verification guidance for the business doing the buying.

Two distinct signaling mechanisms sharing one container

The reason this pairing shows up in research settings at all is that the two compounds act on different receptor systems. Tesamorelin is a stabilized analog of growth-hormone-releasing hormone — a large peptide, structurally related to GRF(1-44), that research describes as acting at the GHRH receptor. Ipamorelin is something else entirely: a short pentapeptide studied as a selective agonist at the growth hormone secretagogue receptor, the same receptor family that ghrelin acts on. Published research has examined GHRH analogs and growth hormone secretagogues as complementary rather than redundant tools, since they engage separate upstream pathways. Studies indicate the two mechanisms are distinguishable in laboratory models; that is a statement about receptor pharmacology, not a performance claim, and none of it establishes a human use.

For your purposes as a buyer, the relevant fact is chemical, not pharmacological. Tesamorelin has a molecular mass in the range of roughly 5,100 daltons. Ipamorelin sits near 712 daltons. That is approximately a seven-fold difference in mass. Two molecules that far apart behave very differently on a chromatography column, in solution, and in a lyophilization cycle — which is precisely why a single combined "strength" figure on a blend label is close to meaningless.

What a strength figure on a blended label should actually state

A defensible blend label gives the mass of each peptide separately. "Tesamorelin 10mg / Ipamorelin 10mg" is a specification. "20mg blend" is a marketing figure. The difference matters because a supplier can hit a combined total while being substantially off on the ratio, and nothing on the label would reveal it.

Ratio is the second half of the specification. Research laboratories selecting a blended preparation are generally selecting a ratio, not just a total. If a supplier cannot tell you the intended ratio and show you an assay confirming the batch met it, you are buying an unspecified product. Ask whether the ratio is verified per batch or assumed from the compounding step — those are very different levels of rigor, and only one of them is auditable.

The third element is net peptide content. Chromatographic purity — the HPLC number most suppliers lead with — describes what fraction of the peptide material is the target molecule. It does not describe how much of the vial's total mass is peptide at all. Lyophilized peptide powder carries residual water and counterions (acetate or trifluoroacetate, depending on the purification route), and that mass is real mass sitting in the vial. A batch with excellent chromatographic purity can still carry a meaningfully lower net peptide content. For blends this compounds, because two components each carry their own counterion load.

Concentration, in the mg-per-mL sense, is downstream of all of this: it is a function of the declared mass in the vial and whatever volume the receiving laboratory elects to use. That volume is the lab's decision under its own protocols, and Real Peptides does not advise on it. The supplier's responsibility stops at an accurate, verified mass declaration — and that is exactly what you should be grading suppliers on.

Why purity verification gets harder when peptides share a vial

Single-compound HPLC is a mature, routine analysis. Blends introduce complications that an underequipped lab will quietly skip.

First, separation. A method developed for a single peptide may not resolve both components cleanly, and if a related-substance impurity from one peptide co-elutes near the main peak of the other, the resulting chromatogram can misread in either direction. Proper blend analysis uses a method validated for the specific combination, not a generic gradient.

Second, identity. Purity says a peak is pure; it does not say what the peak is. Mass spectrometry confirms molecular identity, and with a seven-fold mass difference between these two peptides, MS confirmation is straightforward when a lab actually runs it. Ask whether identity is confirmed per batch for both components or inferred from the supplier's input materials.

Third, quantitation. Confirming that each peptide is present at its declared mass requires quantitative assay against a reference, not just a relative-area percentage. A certificate reporting "99% purity" for a blend without per-component quantitation is reporting something ambiguous.

Fourth, the non-chromatographic panel. Sterility, endotoxin, bioburden, heavy metals, residual solvents, and moisture are batch properties that do not care how many peptides are in the vial — but they are the panel most often missing from blend documentation, because blends are frequently assembled a step removed from the original synthesis and the downstream handler never re-tested.

Stocking separate vials versus stocking a pre-blended vial

Many buyers assume a blend is simply more convenient. From an inventory and verification standpoint, the tradeoffs run both directions:

This is one reason many wholesale catalogs, including the Real Peptides lineup, are organized around single-compound vials with full per-compound documentation rather than pre-mixed combinations. It keeps verification clean and keeps the buyer's own records defensible.

Stability and handling questions that scale with blends

Lyophilized peptides are generally shipped and stored as dry powder, and the durable rule is simple: the fewer unknowns in the vial, the fewer stability variables you inherit. With a blend you are asking the supplier to stand behind the dry-state stability of two molecules of very different size and structure under the same lyophilization cycle, the same stopper and seal, and the same shipping conditions.

Questions worth putting in writing before a first order: Was the batch lyophilized as a blend or compounded after the fact? Is there batch-matched stability data, or only a storage recommendation? What are the cold-chain conditions in transit, and what happens if a shipment arrives warm? How is the batch number carried through from the assay to the label on the individual vial — so that when you pull a vial off your shelf eight months later, you can still retrieve the exact certificate that covers it?

That last point is the one buyers underweight and later regret. Traceability is not a nice-to-have; it is the only thing that lets you answer a customer's question about a specific vial without guessing.

Compliance questions a blended SKU raises for your business

This section is informational and is not legal advice. Blended research compounds sit in a documentation category that deserves a direct conversation with your own counsel, and the right posture is to treat every regulatory point as an open question rather than a settled fact.

The questions to bring to your attorney and, where relevant, your state board: How does your jurisdiction characterize the resale of research-use-only materials, and does that characterization change when a product is a multi-component preparation rather than a single compound? What labeling and record-keeping obligations attach to your business specifically, as distinct from your supplier's? What do your insurer and your merchant processor require of a research-chemical catalog? If you hold a professional license, what does your board say about the relationship between that license and a product-sales business?

No supplier — including Real Peptides — can answer those for you, and any supplier who claims to is telling you something about their judgment. What a supplier can do is make sure the documentation you need to answer them is in your hands before you buy, not after.

What Real Peptides does differently

Real Peptides builds the Wholesale Partner Program around verification the buyer can perform independently. Compounds are tested to 99%+ HPLC purity. Every batch runs a 7-panel test, not a single-assay spot check. Certificates of analysis are publicly verifiable — you can read the lab results yourself, before you place an order, without requesting them from a rep and without paying for them as an add-on. That last point separates a real documentation practice from a stated one: a COA that exists only after purchase, or only behind a sales conversation, is not a verification tool.

Pricing works the same way. Tier structures are stated rather than quoted case by case, which lets you model catalog economics before you commit instead of negotiating blind against a number you cannot compare. Fulfillment runs domestically, with orders shipping in 5–7 days from a US operation.

The application is three steps. Apply with your business details, get reviewed for program fit, and receive wholesale tier access. All compounds are supplied for research use only, and the catalog is organized by single compounds with per-compound documentation rather than unspecified combination products.

If your business buys research peptides at volume and you are tired of chasing certificates that should have been public from the start, the Wholesale Partner Program application is the next step — it takes a few minutes, and the tier structure is visible to you once you are approved.

For the two compounds discussed here, Real Peptides lists Tesamorelin 10mg and Ipamorelin 10mg as separate single-compound vials, each with its own batch documentation; buyers researching adjacent GHRH-analog chemistry often also review CJC-1295 No DAC 10mg, and the broader Growth Factor & Tissue Signaling Research collection covers the rest of that category.